[The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
作者信息
Schatz H
机构信息
Berufsgenossenschaftliche Kliniken Bergmannsheil, Universitätsklinikum der Ruhr-Universität Bochum.
出版信息
Dtsch Med Wochenschr. 2005 Aug 5;130(31-32):1825-30. doi: 10.1055/s-2005-871905.
PMID:16052448
Abstract
摘要
相似文献
1
[The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
Dtsch Med Wochenschr. 2005 Aug 5;130(31-32):1825-30. doi: 10.1055/s-2005-871905.
2
[PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
Lakartidningen. 2006;103(35):2454-5.
3
Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
Int J Clin Pract. 2007 Jul;61(7):1160-9. doi: 10.1111/j.1742-1241.2007.01396.x. Epub 2007 May 18.
4
Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
Metab Syndr Relat Disord. 2009 Apr;7(2):79-81. doi: 10.1089/met.2008.0092.
5
[Too positive comment on glitazones].
Ugeskr Laeger. 2007 Feb 19;169(8):733; author reply 733.
6
[How does the PROactive Study change therapy of diabetes?].
MMW Fortschr Med. 2005 Oct 13;147(41):6.
7
[Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Duodecim. 2003;119(20):1921-3.
8
Diabetes prevention: still no effective drugs.
Prescrire Int. 2007 Dec;16(92):258.
9
Does intensive glycemic control improve cardiovascular outcomes?
Nat Clin Pract Endocrinol Metab. 2008 Oct;4(10):529. doi: 10.1038/ncpendmet0953.
10
[World news in age-related diabetes: blood sugar lowering can improve prognosis].
MMW Fortschr Med. 2005 Sep 22;147(38):1.
Zotero 插件